
Editor's Note: RET fusions are rare oncogenic driver alterations in NSCLC. As the first RET inhibitor approved in China, pralsetinib has the ARROW study as a key foundation of its clinical evidence. A post hoc reanalysis presented at ESMO 2026 showed that first-line pralsetinib provides significant benefits in tumor shrinkage and disease control, while also improving tumor-related symptoms and supporting both efficacy and quality of life. Oncology Frontier invited Professor Yilong Wu from Guangdong Provincial People's Hospital to interpret the findings. He emphasized that results from single-arm studies should not be directly compared across trials and that baseline imbalances must be taken into account. These findings provide important evidence supporting first-line treatment of advanced RET fusion-positive NSCLC.
RET fusions are important oncogenic driver alterations in non-small cell lung cancer (NSCLC), occurring in approximately 1%–2% of patients. Highly selective RET inhibitors have now become first-line treatment options for patients with advanced RET fusion-positive NSCLC.
Pralsetinib was the first highly selective RET inhibitor approved in China. The ARROW study established the clinical value of pralsetinib as a highly selective RET inhibitor, and the subsequent randomized Phase III AcceleRET-Lung study further clarified its role in first-line treatment.
As an early-phase, single-arm Phase I/II study, ARROW initially enrolled only patients in the treatment-naive cohort who were considered unsuitable for platinum-based chemotherapy, before subsequently relaxing this restriction. This resulted in a relatively heterogeneous baseline population. During its early assessment, the European Medicines Agency (EMA) noted that this enrollment strategy could have affected the efficacy observed in the treatment-naive cohort. Therefore, although pralsetinib demonstrated highly impressive results in the final ARROW analysis, its clinical value may still have been underestimated.
At the 2026 European Society for Medical Oncology (ESMO) Congress, two reanalyses of the ARROW study were presented. One reviewed patients’ first-line treatment histories and compared clinical outcomes between pralsetinib and other first-line regimens; the other evaluated changes in health-related quality of life (HRQoL) during pralsetinib treatment. Oncology Frontier invited Professor Yilong Wu, the Chinese lead investigator of the ARROW study, to comment on these findings and provide further insight into the ARROW study and the real-world performance of pralsetinib.
01
Reanalysis of First-Line Efficacy: Benefits in Tumor Response and Disease Control
This post hoc analysis retrospectively reviewed first-line treatment records from patients in the ARROW study and included 279 patients with RET fusion-positive NSCLC. Of these, 116 received pralsetinib as first-line treatment within the study, while 163 had received first-line chemotherapy, immune checkpoint inhibitors, or multikinase inhibitors before enrollment in ARROW and subsequently received pralsetinib in the study.
A key strength of this analysis is that, whereas the original ARROW study reported pralsetinib efficacy separately in treatment-naive and previously treated populations based on prior treatment history, without a comparator group, the current analysis additionally reviewed first-line treatment outcomes among previously treated patients. These outcomes were then used as a reference, enabling a comparison between pralsetinib and other first-line treatments within the ARROW study population.
Among patients with measurable lesions, investigator-assessed results showed that the ORR in the pralsetinib group was approximately 2.8 times that in the other first-line treatment group (75.5% vs. 26.5%). Median time to progression (TTP) was 18.7 months versus 6.8 months (HR = 0.30), respectively. The higher response rate, together with the significantly prolonged TTP, indicates that the benefits of first-line pralsetinib encompass both tumor shrinkage and sustained disease control.
In the original ARROW study, median progression-free survival (PFS) among treatment-naive patients was 12.1 months, with disease progression or death counted as an event. TTP, by contrast, uses objective disease progression as the event and focuses specifically on control of tumor progression, providing additional evidence for interpreting the previously reported PFS results.
Regarding subsequent treatment, median time to next treatment or death (TTNT-D) was 50.1 months in the pralsetinib group versus 10.0 months in the other first-line treatment group (HR = 0.23; 95% CI: 0.16–0.34).
TTNT-D measures the time from initiation of first-line treatment during which patients remain alive without requiring another line of therapy. It reflects disease control beyond radiographic changes and is more closely aligned with how clinicians assess treatment benefit. The markedly longer TTNT-D further highlights the role of pralsetinib in first-line treatment.
Treatment durability also showed a clear advantage. Median time to treatment discontinuation (TTD) was 26.6 months in the pralsetinib group versus 6.0 months in the other first-line treatment group (HR = 0.19; 95% CI: 0.13–0.28). The HRs for TTP, TTNT-D, and TTD were all no greater than 0.30, suggesting that pralsetinib offers substantial advantages in disease control, treatment persistence, and the timing of transition to subsequent therapy.
02
Beyond Tumor Control: Multiple Symptoms Improve in Treatment-Naive Patients
Evaluation of long-term treatment should also take patients’ symptom burden into account. In ARROW, the EORTC QLQ-C30 questionnaire was used to assess symptoms and functional status during pralsetinib treatment. In the overall analysis population, the median time to first improvement in pain was 1.9 months, while the median time to first improvement in fatigue and global health status was 2.1 months for both, suggesting that some patients experienced symptomatic improvement early during treatment.
A total of 127 patients had paired assessments at baseline and Week 44. Of these, 59 were treatment-naive, 56 had previously received platinum-based treatment, and 12 had previously received other non-platinum-based treatment.
Among treatment-naive patients, mean scores for fatigue, pain, dyspnea, and insomnia decreased from baseline by 11.7, 13.0, 18.4, and 16.4 points, respectively. All four improvements met the 10-point threshold for clinical significance defined in the poster. The dyspnea score analysis included 58 patients. The mean improvement across all four symptoms was greater in treatment-naive patients than in those who had previously received platinum-based treatment.
These findings complement the tumor-related endpoints by demonstrating additional patient benefits: the value of first-line pralsetinib is also reflected in reduced symptom burden during treatment, making sustained disease control and improvements in patients’ daily experience complementary treatment goals.
03
Expert Commentary

Professor Yilong Wu
Guangdong Provincial People’s Hospital
Efficacy estimates from single-arm studies should be interpreted in the context of the study population and design. Early clinical evidence for RET inhibitors has primarily come from single-arm studies. With relatively limited sample sizes and no randomized control groups, efficacy estimates may be subject to substantial random variation and influenced by patient selection and baseline prognostic factors. Furthermore, eligibility criteria, treatment lines, and assessment methods differ across studies. Therefore, directly comparing ORRs or median PFS across different single-arm studies has limited value in determining the relative efficacy of drugs and may even lead to differences between patient populations being mistaken for differences in treatment efficacy.
The ARROW study had a complex baseline population, and patient survival outcomes were influenced by both the effects of the drug and patients’ underlying prognostic characteristics. If this context is overlooked and its PFS results are directly compared with those of other studies or previously treated cohorts, the first-line treatment value of pralsetinib may be underestimated.
In the current ARROW reanalysis, the HRs for TTP, TTNT-D, and TTD with pralsetinib were 0.30, 0.23, and 0.19, respectively. All three endpoints demonstrated substantial benefits, with consistent trends across outcomes. The concurrent HRQoL analysis also showed improvements in symptoms such as fatigue, pain, and dyspnea, further highlighting patients’ experiences during sustained treatment.
Together, these findings provide a more comprehensive understanding of the value of first-line pralsetinib and further support the clinical decision to prioritize pralsetinib as a first-line treatment for eligible patients.
